background pattern

Precision-designed
kinase inhibitors
that reach where others can't, including the brain.

 
PIPELINE

A precisely crafted pipeline, accelerating the pace of drug discovery.

With hundreds of thousands of experimental data points and robust target validation, Voronoi rapidly identifies and optimizes promising drug candidates. Discover how innovation unfolds in our pipeline.

 
Publications

Science with purpose.

From design to clinic delivering targeted therapies that matter. Explore our research and breakthroughs.

background pattern
OUR Approach

VORONOMICS-Based Drug Design

VORONOMICS, a proprietary platform, revolutionizes the drug development process, enabling the rapid discovery of development candidates with exquisite selectivity and brain penetration that are unprecedent.

Latest Highlights

World Conference on Lung Cancer 2026 (WCLC2026)

Voronoi is excited to participate in the WCLC 2026

  • calendar icon Date & Time: September 12 - 15, 2026
  • location icon Location: Seoul, Republic of Korea

Latest News

  • 2026.09.15
보로노이, VRN11 C797S·뇌전이 환자에서 차별화된 항종양 효과 확인

보로노이(310210)는 서울에서 개최된 세계폐암학회(WCLC 2026)에서 차세대 EGFR 표적치료제 VRN11의 임상 1상 결과를 미니 오랄(Mini Oral) 세션을 통해 발표했다고 15일 밝혔다.

  • 2026.09.14
보로노이, VRN11 태국 1b/2상 IND 승인…글로벌 임상 확대

보로노이(310210)는 차세대 EGFR 표적치료제 ‘VRN11’의 글로벌 1b/2상 임상시험계획(IND)이 태국 식품의약품청(FDA Thailand)의 승인을 받았다고 14일 공시를 통해 밝혔다.